Annovis Bio, Inc.NYSE: ANVS

Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study

· Issued by Annovis Bio, Inc. via GlobeNewswire

Summary by 6ix AI

Annovis Bio, which is developing buntanetap, an investigational once-daily pill for diseases such as Alzheimer's and Parkinson's, announced on November 17, 2026 that an independent Data and Safety Monitoring Board (DSMB, an outside panel that reviews trial safety) has recommended that its Phase 3 DUET-AD trial in early Alzheimer's disease continue without modification.

Key details

  • The recommendation followed a 12-month review of safety data accumulated through September 22, 2026, from 861 patients at different stages of dosing.
  • It is the DSMB's second consecutive positive recommendation for DUET-AD, following its positive 6-month feedback announced in February 2026.
  • Chief Scientific Officer Cheng Fang, Ph.D., said Annovis will report detailed DUET-AD safety outcomes alongside the 6-month symptomatic results.

What’s still pending

  • The last patient's last visit for the 6-month treatment period is expected on December 31, 2026.
  • Database lock (the point when trial data are finalised for analysis) is expected on February 8, 2027.
  • 6-month topline results are expected in March 2027.

6ix AI wrote this summary from the release below and checked it against the release.

MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company’s pivotal Phase 3 trial in early AD, after the review of the study’s safety data. This 12-month review follows the DSMB’s positive 6-month feedback, which was announced in February 2026.

The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing.

“A second positive recommendation from the DSMB in such a large population further reinforces our confidence in buntanetap’s safety profile,” said Cheng Fang, Ph.D., Chief Scientific Officer at Annovis. “This milestone comes at an important time. As we approach the 6-month data readout and prepare for regulatory submission, a demonstrated safety at scale is essential. In March, we will report detailed DUET-AD safety outcomes alongside the 6-month symptomatic results.”

DUET-AD (NCT06709014) remains on track, with last patient, last visit for the 6-month treatment period expected on December 31, 2026, database lock on February 8, 2027, and 6-month topline results in March 2027.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

View original source (GlobeNewswire)Annovis Bio, Inc. on 6ix

Earlier from Annovis Bio

All Annovis Bio news releases